Last reviewed · How we verify

BMN 111 — Competitive Intelligence Brief

BMN 111 (BMN 111) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CNP analog. Area: Rare genetic disorders / Endocrinology.

phase 3 CNP analog Natriuretic peptide receptor B (NPR-B) Rare genetic disorders / Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

BMN 111 (BMN 111) — BioMarin Pharmaceutical. BMN 111 is a C-type natriuretic peptide (CNP) analog that activates natriuretic peptide receptor B (NPR-B) to promote bone growth and increase height.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BMN 111 TARGET BMN 111 BioMarin Pharmaceutical phase 3 CNP analog Natriuretic peptide receptor B (NPR-B)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CNP analog class)

  1. BioMarin Pharmaceutical · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BMN 111 — Competitive Intelligence Brief. https://druglandscape.com/ci/bmn-111. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: